Prolonged low-dose infusion for gemcitabine: a systematic review

Dehua Zhao 1
Jing Chen 1
Mingming Chu 2
Jisheng Wang 1

1Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang 621000, People’s Republic of China; 2Department of Clinical Pharmacy, The Second Affiliated Hospital of Third Military Medical University, Chongqing 400037, People’s Republic of China

Background: The present standard dose of gemcitabine (Gem), a pyrimidine antimetabolite, is 1,000–1,250 mg/m², and the infusion time is 30 min. However, pharmacological studies have demonstrated that Gem with prolonged infusion could attain a better accumulation rate of Gem triphosphate (active metabolites of Gem), indicating that Gem with prolonged infusion is superior to 30-min infusion. Thus, this systematic review aims to provide some references for Gem administered as a prolonged infusion.

Methods: We searched electronic databases, including PubMed, EMBASE, Cochrane Library, and CNKI, for trials. Keywords were “Gem,” “prolonged infusion,” and “low-dose.” In addition, we used the Cochrane Handbook V5.1.0 and methodological index for non-randomized studies to evaluate the quality of randomized controlled trials (RCTs) and non-RCTs, respectively. Furthermore, Cochrane Collaboration guidelines and the PRISMA statement were adopted.

Results: We systematically reviewed 19 studies (5 RCTs and 14 non-RCTs). All studies assessed the efficacy and safety of Gem administered as a prolonged low-dose infusion (P-LDI) and reported that Gem administered as P-LDI was effective and well tolerated.

Conclusion: Gem administered as P-LDI is effective, safe, and economical, especially suited for patients with poor performance status or without good economic condition.

Keywords: gemcitabine, low dose, prolonged infusion, pharmacokinetics

Introduction

Gemcitabine (Gem) is related to specific inhibition of DNA synthesis and commonly used as therapy for various solid tumors, including non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma, and pancreatic cancer.1 Reportedly, Gem is a pro-drug that needs to be phosphorylated to Gem triphosphate by deoxycytidine kinase (DK).2 DK is a rate-limiting enzyme during the activation of Gem and saturated at Gem concentration >20 μmol/L.3 Thus, a linear correlation between the intracellular accumulation of Gem triphosphate and Gem concentration can only be expected at the plasma concentration below 20 μmol/L.2 In addition, it has been established that the plasma concentration of Gem following 30-min infusion often exceeds the saturation concentration of DK. Hence, the short-term infusion leaves a majority of the drug unmetabolized and might not be the best method for Gem administration. Conversely, by prolonging the infusion time, the accumulation rate of Gem triphosphate could be elevated and, possibly, achieve better clinical efficiency.4

For the standard 30-min infusion, the maximum tolerated dose (MTD) is ≥1500 mg/m².5 With the infusion time prolonging for 3, 4, 6, or 24 h, MTD significantly falls to
450, 200, 300, and 180 mg/m², respectively; this phenomenon can be explained by saturation of DK.

In clinical practice, Gem administered as a 30-min infusion of 1,000–1,250 mg/m² is the standard regimen. However, several trials have demonstrated that another type of administration [prolonged low-dose infusion (P-LDI)] exhibits a comparable activity and toxicity compared with a 30-min infusion of the standard dose (30-min SDI). Previously, we suggested that P-LDI was superior in terms of the overall response rate, experienced less grade 3/4 thrombocytopenia and leukopenia compared with 30-min SDI, and could be a viable treatment option for advanced NSCLC. However, whether the same is also applicable to other cancer types remains unclear. Hence, this systematic review of the current literature aims to provide some references for Gem administered as a prolonged infusion and supports the need for further investigation regarding both clinical efficiency and safety.

**Methods**

**Search strategy**
We searched electronic databases, including PubMed, EMBASE, Cochrane Library, and CNKI. The search was limited to studies written in English and Chinese, and articles published from the earliest entries of any databases until February 2019. Keywords were “gemcitabine,” “GEM,” “prolonged low-dose infusion,” “prolonged infusion,” “long infusion,” “low dose,” and “standard dose”. Furthermore, manual searching of references from the included studies and the websites of clinical trials were examined for additional relevant articles.

**Eligibility criteria**
In this review, the inclusion criteria were as follows: studies were clinical trials written in English and Chinese, and Gem administered as P-LDI. However, we excluded case reports, conference abstracts, literature reviews, meta-analyses, and animal model studies.

**Data extraction and data items**
Data were extracted from eligible studies and reviewed independently by two investigators. The items extracted from each study included first author, publication date, journal, study design, tumor types, chemotherapy regimens, number of patients, age, sex, overall survival (OS), progression-free survival (PFS), and 1-year survival rate (1-YSR). In addition, we contacted the authors of the primary studies for missing data; if we were unable to contact the authors, we excluded the study.

**Reviewing quality based on the checklist**
We used the Cochrane Handbook V5.1.0 and methodological index for non-randomized studies (MINORS) to assess the quality of randomized controlled trials (RCTs) and non-RCTs, respectively.

**Results**

**Eligible studies**
Using the search strategy, we identified 1242 studies. Then, we examined the title, abstract, and excluded 1214 studies. Finally, we included 19 studies after a full-text review (Figure 1). Table 1 summarizes the characteristics of the selected studies.

**Quality and publication bias of included trials**
In this systematic review, we selected 5 RCTs and 14 non-RCTs. We used Cochrane Handbook V5.1.0 and MINORS for RCTs and non-RCTs, respectively, to assess the risk of bias of the selected studies. Of five RCTs, two trials detailed the sequence generation and blinding, but none detailed the allocation concealment, selective reporting, or other sources of bias (Table 2). Of 14 non-RCTs, MINORS scores ranged 6–11, demonstrating the existence of a significant amount of methodological heterogeneity among studies (Table 1).

**Clinical application of gem in P-LDI**
Based on possible advantages of Gem administered as P-LDI, several phase I and II clinical trials have reported significant antitumor activity of Gem administered as P-LDI. Table 3 presents the spectrum of diseases, including cancer of the lung, pleural, breast, pancreas, gallbladder, bladder, sarcomas, and soft tissue.

**NSCLC**
Beniwal investigated the efficacy and safety of the combination of Gem administered as P-LDI compared with 30-min SDI and carboplatin in patients with NSCLC. Overall, 60 patients with stage IIIa/IV NSCLC were randomly assigned to P-LDI and 30-min SDI. The ORR was 40% and 36.6%, SDR was 33.3% and 36.3%, PDR was 26.6% and 26.6%, PFS was 5.5 and 5.4 months, OS was 9.7 and 10.7 months, and 1-YSR was 33.7% and 36.6% in 30-min
SDI and P-LDI, respectively. Notably, grade 3/4 toxicities were rare. Owing to good efficacy, low toxicity, and lower drug costs, Gem administered as P-LDI is an attractive option for the elderly or those without good economic condition.

Vrankar presented a phase II randomized trial of induction chemotherapy comparing Gem in two different schedules with cisplatin followed by concurrent radiochemotherapy in locally advanced NSCLC. In their study, toxicities were comparable and mild in both arms. The PFS was 15.7 and 18.9 months, OS was 24.8 and 28.6 months, 1-YSR was 73.1% and 81.5%, and 3-YSR was 30.8% and 44.4% in 30-min SDI and P-LDI, respectively. Although we observed a trend toward better efficacy of the treatment with prolonged infusion, the difference between the two arms was not statistically significant.

In the trial conducted by Zwitter, the PFS was 5.5 and 6 months, OS was 10.1 and 10 months, and 1-YSR was 46.6% and 41.1% for 30-min SDI and P-LDI, respectively. Moreover, grade ≥3 toxicities were rare. The study suggested that P-LDI could be preferred for incurable cancer among economically deprived patients. In addition, other trials demonstrated the efficacy and safety of Gem administered as P-LDI, suggesting that P-LDI was effective and well tolerated for NSCLC. Furthermore, a meta-analysis of 6 RCTs reported that P-LDI was superior in terms of ORR, experienced less grade 3/4 thrombocytopenia and leukopenia compared with 30-min SDI, and could be a viable treatment option for advanced NSCLC.

**Malignant pleural mesothelioma**

After favorable experience with Gem administered as P-LDI for advanced NSCLC, Kovac conducted a phase II trial on patients with malignant pleural mesothelioma (MPM); 78 patients were treated with Gem administered as P-LDI plus cisplatin for four cycles. Grades 3/4 toxicities were anemia in 2 patients, neutropenia in 18 patients, and nausea/vomiting in 1 patient. The PFS, OS, 1-YSR, 2-YSR, and 3-YSR were 8 months, 17 months, 67.3%, 32.7%, and 19.8%, respectively. Hence, Gem administered as P-LDI plus cisplatin could be considered for the primary treatment of MPM, especially in economically deprived populations.

Arrieta conducted another phase II trial of Gem administered as P-LDI plus cisplatin in patients with advanced MPM. The PFS and OS were 6.9 and 20.7 months. In
| Trial                          | Study design | Patients | Male/ Female | Age          | Tumor type | Chemotherapy regimens                                                                 | Endpoints assessed | MINORS Score |
|-------------------------------|--------------|----------|--------------|--------------|------------|--------------------------------------------------------------------------------------|-------------------|-------------|
| Beniwal SK, 2012              | RCT          | 30       | 26/4         | 53.3 (35–65) | NSCLC      | GEM (1,000 mg/m² in 30 min d1, d8), CBP (AUC 5 d1)                                    | ORR SDR PDR PFS OS | I-YSR N/A  |
|                               |              | 30       | 28/2         | 54.5 (40–70) |            | GEM (350 mg/m² in 6 h d1, d8) + CBP (AUC 5 d1)                                       |                   | N/A         |
| Vrankar M 2014                | RCT          | 52       | 39/13        | 58 (42–72)   | NSCLC      | GEM (1250 mg/m² in 30 min d1, d8), CBP (AUC 5 d1)                                    | PFS OS I-YSR ORR   | N/A         |
|                               |              | 54       | 44/10        | 57 (30–77)   |            | GEM (250 mg/m² in 6 h d1, d8) + DDP (75 mg/m² d2)                                   |                   | N/A         |
| Zwitter M 2009                | RCT          | 125      | 95/30        | 58 (41–77)   | NSCLC      | GEM (1250 mg/m² in 30 min d1, d8) + DDP (75 mg/m² d2)                               | CRR PRR SDR PDR I-YSR OS | N/A         |
|                               |              | 124      | 93/31        | 59 (40–79)   |            | GEM (250 mg/m² in 6 h d1, d8) + DDP (75 mg/m² d2)                                   |                   | N/A         |
| Zwitter M, 2010               | RCT          | 57       | 46/11        | 66 (41–8)    | NSCLC      | GEM (1250 mg/m² in 30 min d1, d8) + DDP (60 mg/m² d2)                               | PFS CRR PRR OS I-YSR | N/A         |
|                               |              | 55       | 37/18        | 65 (49–80)   |            | GEM (200 mg/m² in 6 h d1, d8) + DDP (60 mg/m² d2)                                   |                   | N/A         |
| Wu ZY 2014                    | Non-RCT      | 37       | 28/9         | 58 (40–79)   | NSCLC      | Gem (250 mg/m² in 6 h d1, d8) + CBP (AUC 5 d1)                                       | PFS ORR OS SDR     | 10          |
| Narayanan P 2009              | Non-RCT      | 75       | 60/15        | 65 (60–79)   | NSCLC      | Gem (350 mg/m² in 4 h d1, d8) + CBP (AUC 5 d1)                                       | OS I-YSR CRR PDR PDR ORR | 8           |
| Xiong J P 2008                | Non-RCT      | 58       | 39/19        | 61 (28–73)   | NSCLC      | Gem (250 mg/m² in 6 h d1, d8) + DDP (75 mg/m² d2)                                   | ORR CRR PFS OS I-YSR | 11          |
| Zwitter M 2005                | Non-RCT      | 32       | 22/10        | 58 (31–76)   | NSCLC      | Gem (250 mg/m² in 6 h d1, d8) + DDP (75 mg/m² d2)                                   | ORR CRR PFS OS I-YSR | 9           |
| Kovac V 2012                  | Non-RCT      | 78       | 58/20        | 58 (33–82)   | MPM        | Gem (250 mg/m² in 6 h d1, d8) + DDP (75 mg/m² d2)                                   | CRR PDR SDR PFS OS I/2/3-YSR | 11          |
| Arrieta O 2014                | Non-RCT      | 39       | 26/13        | 59.7 (33–84) | MPM        | Gem (250 mg/m² in 6 h d1, d8) + DDP (35 mg/m² d1, d8)                               | CRR PDR SDR PFS OS | 9           |
| Khaled H 2008                 | Non-RCT      | 57       | 41/16        | 55 (37–77)   | Bladder cancer | Gem (250 mg/m² in 6 h d1, d8) + DDP (70 mg/m² d2)                                   | CRR PDR ORR PFS OS | I-YSR      |
|                               |              | 60       | 48/12        | 62 (40–80)   | Bladder cancer | Gem (1250 mg/m² in 30 min d1, d8) + DDP (70 mg/m² d2)                               | CRR PDR SDR PDR ORR PFS OS I-YSR | N/A         |
|                               |              | 60       | 44/16        | 60 (40–85)   |            | Gem (250 mg/m² in 6 h d1, d8) + DDP (70 mg/m² d2)                                   |                   | N/A         |
| Guan HH 2014                  | Non-RCT      | 26       | 12/14        | 55 (46–71)   | NPC        | Gem (250 mg/m² in 6 h d1, d8) + NDP (80 mg/m² d1)                                   | CRR PDR SDR PDR ORR PFS I-YSR | 8           |
| Eckel F 2003                  | Non-RCT      | 18       | 9/9          | 68 (51–81)   | PC         | Gem (100 mg/m² in 24 h d1, d8, d15)                                                 | PRR ORR PFS        | 6           |
| Von DS 2005                   | Non-RCT      | 19       | 8/11         | 63 (30–83)   | GBC        | Gem (100 mg/m² in 24 h d1, d8, d15)                                                 | PRR SDR PFS OS I-YSR | 7           |

(Continued)
Addition, the functional, physical, and emotional roles, dyspnea, insomnia, and pain symptom scales were improved, and the most commonly graded 3/4 adverse effects were neutropenia (24.4%), lymphopenia (14.6%), thrombocytopenia (14.7%), and anemia (12.2%).

**Bladder cancer**

A phase II trial evaluated the efficacy and tolerability of a combination of Gem administered as P-LDI and cisplatin in patients with bladder cancer. The ORR, complete remission (CR), and partial remission (PR) were 59.4%, 27%, and 50%, respectively. At a median observation time of 12 months, the PFS, OS, and 1-YSR were 7.2 months, 11.5 months, and 28%, respectively. Both hematological and non-hematological toxicities were treatable and not severe. The study suggested that Gem administered as P-LDI plus cisplatin is effective and safe for bladder cancer.

In a randomized phase II study, 120 untreated patients with stage III/IV bladder cancer were randomized to receive either Gem in a 30-min SDI (arm 1) or Gem as P-LDI (arm 2), with the same dose of cisplatin. In 120 patients, the ORR, CR, PR, PFS, OS, and 1-YSR were 33.6% and 41.7%, 5% and 11.7%, 28.3% and 30%, 24 and 26 months, 16 and 12 months, and 54.7% and 49.9% in arms 1 and 2, respectively. The main toxicities were similar in both arms with no statistically significant differences. Accordingly, Gem administered as P-LDI in combination with cisplatin is an effective and well-tolerated regimen for patients with advanced bladder cancer.

**Nasopharyngeal carcinoma**

Guan reported that Gem administered as P-LDI plus nedaplatin was effective in the treatment of metastatic nasopharyngeal carcinoma and yielded relatively mild side effects. In the study, the ORR, 1-YSR, and PFS were 80.7%, 57.7%, and 7.0 months, respectively. In addition, hematological toxicities were well tolerated, and the occurrence of grade I/II leukocytopenia and thrombocytopenia were 53.8% and 38.5%, respectively. Of note, grade III/IV leukocytopenia and thrombocytopenia were not observed.

**Pancreatic carcinoma**

In a phase II trial, 18 patients with advanced pancreatic carcinoma were treated with Gem (100 mg/m²) infused over 24 h on days 1, 8, and 15. All patients were assessable for...
therapeutic response. Of note, grade 3 neutropenia and thrombocytopenia occurred in 1 patient each. The median PFS was 4.4 months, ORR was 16.7%, and the symptom and quality-of-life scores were improved. The study suggested that patients might benefit from 24-h Gem.

**Gallbladder and biliary tract carcinoma**

Based on a phase I study in patients with NSCLC, Von24 conducted a phase II trial of weekly 24-h infusion of Gem in patients with advanced gallbladder and biliary tract carcinoma (GBC). In the study, 18 patients were evaluable for response. The 1-YSR, PFS, and OS were 34%, 3.6 months, and 7.5 months, respectively. Notably, toxicities were mild. Hence, 24-h infusion of Gem at a low dose is effective and safe for the treatment of GBC.

**Breast cancer**

Based on a phase II study conducted by Schmid,25 44 patients with stage II/III breast cancer were treated with NPLD (60 mg/m², d1), docetaxel (75 mg/m², d1), and Gem (350 mg/m² in 4-h infusion, d4). The treatment was repeated every 21 days for a maximum of six cycles. The ORR was 80%, and the tumor diameter decreased from 3.5 cm to 1.4 cm. In addition, breast conservation surgery was performed in 19 patients with an initial tumor size <3 cm and 14 patients with tumor size ≥3 cm. Moreover, modified mastectomies were performed for the remaining patients. The toxicity of the regimen was moderate. Overall, this modified chemotherapy regimen was a highly active and safe regimen for primary chemotherapy in patients with breast cancer, which corroborated the previous study.

Another phase II study of Gem administered as prolonged infusion plus vinorelbine in anthracycline and/or taxane-pretreated metastatic breast cancer reported that the ORR, PFS, and OS were 30.4%, 4.6 months, and 14.5 months, respectively.26 Notably, hematological and non-hematological toxicities were generally moderate. Hence, this regimen represented a therapeutic option for patients receiving second-line therapy for metastatic breast cancer.

**Soft tissue sarcomas**

In a phase II study of Gem in patients with pretreated advanced soft tissue sarcomas,28 the initial dose of Gem was 200 mg/m². The dose escalation to 250 mg/m² was allowed in the case of SD with well tolerated. Overall, 2 patients had PR and 6 had SD for 3–6 months. The median OS was 8 months. The treatment was generally well tolerated and with no treatment-related death.

**Discussion and future perspectives**

As mentioned earlier, DK is saturated at concentrations of 10–20 μmol/L of Gem. The reaction rate is constant at higher concentrations.29 Hence, the MTD and toxicity profile closely depend on the infusion time. In a phase I trial, Pollera6 investigated the maximum tolerated infusion time (MIIT) of prolonged infusion for Gem and reported that the MIIT of the 875 mg/m² group was 1 h and that of the 300 mg/m² group was 6 h. In addition, a phase I trial conducted by Schmid reported that when Gem was administered as a 4-h infusion, the MTD was 400 mg/m², and dose-limiting toxicities (DLTs) were neutropenia, thrombocytopenia, stomatitis, and elevation of liver enzymes. Another phase I study evaluated the MTD of Gem administered as a 3-h infusion.7 The MTD was

### Table 2 Quality evaluation of included RCTs

| Included trials | Sequence generation | Allocation concealment | Blinding | Incomplete data | Selective reporting | Other sources of bias |
|-----------------|---------------------|------------------------|----------|-----------------|---------------------|----------------------|
| Beniwal SK, 2012 | Unclear             | Unclear                 | Unclear  | No              | Unclear             | Unclear              |
| Vrankar M, 2014  | Unclear             | Unclear                 | Unclear  | Yes             | Unclear             | Unclear              |
| Zwitter M, 2009  | Computer-generated sequence of random numbers | Unclear | Single-blind | Yes | Unclear | Unclear |
| Zwitter M, 2010  | Computer-generated sequence of random numbers | Unclear | Single-blind | Yes | Unclear | Unclear |
| Khaled H 2014    | Unclear             | Unclear                 | Unclear  | No              | Unclear             | Unclear              |

**Abbreviation:** RCTs, randomized controlled trials.
| Trials                      | Tumor types | patients | Administration of GEM P-LDI or 30-min SDI | outcomes PFS month | OS month | ORR % | 1-YSR % | Conclusions |
|-----------------------------|-------------|----------|------------------------------------------|-------------------|----------|-------|---------|-------------|
| Benwal SK 2012              | NSCLC       | 30       | 30-min SDI                               | 5.5               | 9.7      | 40    | 33.7    | P-LDI has an equal activity and low toxicity compared with 30-min SDI. |
|                            |             | 30       | P-LDI                                   | 5.4               | 10.7     | 36.6  | 36.6    |                                                        |
| Vrankar M 2014              | NSCLC       | 52       | 30-min SDI                               | 15.7              | 24.8     | 61.5  | 73.1    | A trend towards better efficacy of treatment with P-LDI, but no statistical significance difference. Both schedules had a comparable toxicity profile. |
|                            |             | 54       | P-LDI                                   | 18.9              | 28.6     | 61.1  | 81.5    |                                                        |
| Zwitter M 2009              | NSCLC       | 125      | 30-min SDI                               | 5.5               | 10.1     | 32.8  | 46.6    | P-LDI has an equal activity and low toxicity compared with 30-min SDI. |
|                            |             | 124      | P-LDI                                   | 6.0               | 10.0     | 46.8  | 41.1    |                                                        |
| Zwitter M 2010              | NSCLC       | 57       | 30-min SDI                               | 3.8               | 4.3      | 8.8   | 8.8     | P-LDI has very low toxicity and better efficacy compared with 30-min SDI. |
|                            |             | 55       | P-LDI                                   | 5.6               | 6.8      | 25.5  | 25.5    |                                                        |
| Wu ZY 2014                 | NSCLC       | 37       | P-LDI                                   | 7.0               | 14.0     | 62.2  | N/A     | Gem in P-LDI combined with CBP was efficacious in patients with well tolerated toxicity profiles. |
| Narayanan P 2009            | NSCLC       | 75       | P-LDI                                   | N/A               | 11       | 25.3  | 40      | Gem in P-LDI combined with CBP was effective in advanced NSCLC, and its toxicity was very favorable. |
| Xiong J P 2008              | NSCLC       | 58       | P-LDI                                   | 5.5               | 10.5     | 39.3  | 41.4    | Gem in P-LDI plus DDP was effective in NSCLC treatment. Toxicity, especially myelosuppression, was remarkably mild. |
| Zwitter M 2005              | NSCLC       | 32       | P-LDI                                   | 6.0               | 9.5      | 43.8  | 40      | treatment with Gem in P-LDI plus DDP was feasible. |
| Kovac V 2012               | MPM          | 78       | P-LDI                                   | 8                 | 17       | 50    | 67.3    | Gem in P-LDI plus DDP may be considered for the primary treatment of MPM, especially in economically deprived populations. |
| Arrieta O 2014             | MPM          | 39       | P-LDI                                   | 6.9               | 20.7     | 53.8  | N/A     | Gem in P-LDI plus DDP showed acceptable toxicity and high efficacy with improvement in the quality of life, representing an affordable regimen for the low-income population. |
| Khaled H 2008              | Bladder cancer | 57      | P-LDI                                   | 7.2               | 11.5     | 59.4  | 28      | Gem in P-LDI plus DDP was an effective treatment for advanced bladder cancer. Toxicity, especially myelosuppression, was surprisingly mild. |
| Khaled H 2014              | Bladder cancer | 60      | 30-min SDI                             | 24                | 16       | 33.3  | 54.7    | Gem in P-LDI plus DDP was not inferior to the standard GC regimen with a favorable toxicity profile and less financial costs. |
|                            |             | 60       | P-LDI                                   | 26                | 12       | 41.7  | 49.9    |                                                        |

(Continued)
| Trials      | Tumor types | patients | Administration of GEM P-LDI or 30-min SDI | outcomes | Conclusions |
|-------------|-------------|----------|------------------------------------------|----------|-------------|
|             |             |          |                                          | PFS month | OS month | ORR % | I-YSR % |                        |
| Guan HH 2014 | NPC         | 26       | P-LDI                                    | 7        | N/A      | 80.8  | 58     | Gem in P-LDI plus nedaplatin was effective for nasopharyngeal carcinoma and yielded relatively mild toxicities. |
| Eckel F 2003 | PC          | 18       | P-LDI                                    | 4.4      | N/A      | 16.7  | N/A    | Gem in P-LDI seems to be as active as the 30 min-SDI. Relatively long PFS and improvement of symptom and quality of life scores. |
| Von DS 2005  | GBC         | 19       | P-LDI                                    | 3.6      | 7.5      | 6.0   | 34     | 24 hr Gem at a dose of 100 mg/m² was well tolerated, relatively high rate of disease control. |
| Schmid P 2005 | Breast cancer | 44   | P-LDI                                    | N/A      | N/A      | 80    | N/A    | The evaluated schedule provides a safe and highly effective combination treatment for patients with early breast cancer. |
| Schmid P 1999 | Breast cancer | 20   | P-LDI                                    | 6.3      | 51.9     | 25    | N/A    | Gem in P-LDI plus vinorelbine was an effective treatment in metastatic breast cancer. |
| Schmid P 2005 | Breast cancer | 26   | P-LDI                                    | 4.6      | 14.5     | 30.4  | N/A    | Gem in P-LDI plus vinorelbine was a safe and effective treatment in anthracycline and/or taxane pretreated patients. |
| Spath SE 2000 | STS         | 18       | P-LDI                                    | N/A      | 8        | 11    | 28     | Gem in P-LDI has a favorable toxicity profile and displays antitumor activity in patients with pretreated advanced soft tissue sarcomas. |

**Abbreviations:** N/A, unknown or not measured; MPM, malignant pleural mesothelioma; NPC, nasopharyngeal carcinoma; PC, Pancreatic carcinoma; GBC, gallbladder and biliary tract carcinoma; STS, Soft tissue sarcomas.
defined as 450 mg/m², with myelosuppression and asthenia being DLTs. Moreover, Anderson conducted a phase I study to evaluate the MTD of Gem administered as a 24-h infusion; the dose levels were 10, 20, 40, 80, 120, 180, and 210 mg/m², and the MTD was 180 mg/m², without neutropenia and lethargy as DLTs. Based on the previous studies, the MTD of Gem is heavily dependent on the infusion time. When the infusion time of 3 h, the MTD is 450 mg/m², and when the infusion time increases to 4, 6, and 24 h, the MTD decreases to 400, 300, and 180 mg/m², respectively. Hence, dosage and infusion time should be considered when Gem is administered as a prolonged infusion.

Although a pharmacological advantage is attained by prolonging the infusion time, the clinical efficacy of P-LDI is not superior to 30-min SDI in various clinical studies, which could be associated with genetic polymorphism. Notably, genetic polymorphism could result in different expressions of DK, cellular transporter, and cytidine deaminase from person to person, which could contribute to individual variability in Gem pharmacokinetics and toxicity. Hence, it is imperative to consider both infusion time and genotype in optimizing the Gem triphosphate accumulation.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Aspeslagh S, Stein M, Bahleda R, et al. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anticancer Drugs. 2016;28(3):341–349. doi:10.1097/CAD.0000000000000457
2. Cattel L, Airoldi M, Delprino L, et al. Pharmacokinetic evaluation of gemcitabine and 2′,2′-difluorodeoxyctydine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol. 2006;17:142–147.
3. Sugiyama E, Kaniwa N, Kim SR, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet. 2010;49(8):549–558. doi:10.2165/11532970-00000000-0000
4. Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I study. Invest New Drugs. 2005;23(2):139–146. doi:10.1007/s10637-005-5859-4
5. Fossella FV, Lipman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15:510–316. doi:10.1200/JCO.1997.15.1.310
6. Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m²) and high-dose (875 mg/m²) levels. Invest New Drugs. 1997;15(2):115–121.
7. Maurel J, Zorrilla M, Puertolas T, et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs. 2001;12(9):713–717.
8. Anderson H, Thatcher N, Walling J, Hansen H. Phase I study of a 24 hr infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer. 1996;74(3):460–462. doi:10.1038/bjc.1996.382
9. Dehua Z, Mingming C, Jisheng W, Addison CL. Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer. PLoS One. 2018;13(3):e0193814. doi:10.1371/journal.pone.0193814
10. Beniwal SK, Patel KM, Shukla S, et al. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer. Indian J Cancer. 2012;49(2):202–208. doi:10.4103/0019-509X.108261
11. Martina V, Matjaz Z, Tanja B, et al. Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial. Radioi Oncol. 2014;48(4):369–380.
12. Matjaz Z, Vlijen K, Smrdel U, et al. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized Phase II Clinical Trial. Thorac Oncol. 2009;4:1148–1155. doi:10.1097/JTO.08013e13181acz20f
13. Zwitter M, Kovac V, Rajer M, et al. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial. Anticancer Drugs. 2010;21:662–668. doi:10.1097/CAD.0b013e32833ab7a0
14. Wu ZY, Guan HH, Lin ZX, et al. Combination of low-dose gemcitabine in 6 hr infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small-cell lung cancer. J Chemother. 2014;26(5):306–311. doi:10.1179/1973947813Y.0000000139
15. Narayanian P, Prabhask H, Kurkure P, Parrich P. Treatment of advanced NSCLC (Stage IIB and IV) with low dose gemcitabine and carboplatin-indian experience. Lung Cancer. 2009;64:S57. doi:10.1016/S0169-5002(09)70260-0
16. Xiong JP, Meng M, Qiu F, et al. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer. 2008;60(2):208–214. doi:10.1016/j.lungcan.2007.10.004
17. Zwitter M, Kovac V, Smrdel U, et al. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer. 2005;16(10):1129–1134.
18. Kovac V, Zwitter M, Rajer M, et al. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs. 2012;23(2):230–238. doi:10.1097/CAD.0b013e28234d7a1c
19. Arrieta O, López-Macias D, Mendoza-García VO, et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014;73(5):975–982. doi:10.1007/s00280-014-2429-5
20. Khaled H, Emara ME, Gaafar RM, et al. Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. Urol Oncol Semin Ori Invest. 2008;26(2):133–136. doi:10.1016/j.urolonc.2007.01.013
21. Khaled H, Abutaleb F, Haggag R, et al. Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial. Med Oncol. 2014;31(1):1–6.
22. Guan HH, Yang HK, Zhou L, et al. Clinical observation prolonged infusion of low-dose gemcitabine combined with nedaplatin in treatment of recurrent/metastatic nasopharyngeal carcinoma. New Med. 2014;45(8):555–557.
23. Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24 hr infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. *Cancer Invest*. 2003;21(5):690–694.

24. von Delius DS, Lersch C, Schultefrohlinde E, Mayr M, Schmid RM, Eckel F. Phase II trial of weekly 24 hr infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. *BMC Cancer*. 2005;5(1):61. doi:10.1186/1471-2407-5-61

25. Schmid P, Kroeker I, Jehn C, et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. *Ann Oncol*. 2005;16(10):1624–1631. doi:10.1093/annonc/mdi321

26. Schmid P, Akrivakis K, Flath B, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. *Anticancer Drugs*. 1999;10(7):625–631.

27. Schmid P, Heilmann V, Schulz CO, et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. *J Cancer Res Clin Oncol*. 2005;131(9):568–574. doi:10.1007/s00432-005-0675-y

28. Späth-Schwalbe SE, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. *Anticancer Drugs*. 2000;11(5):325–329. doi:10.1097/00001813-200006000-00002

29. Zwitter M, Kovac V, Smrdel U, et al. Phase I–II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. *Anticancer Drugs*. 2005;16:1129–1134.

30. Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. *Oncologist*. 2008;13(3):261–276. doi:10.1634/theoncologist.2007-0215

31. Metharom E, Galettis P, Manners S, et al. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. *Asia Pac J Clin Oncol*. 2011;7(1):65–74. doi:10.1111/j.1743-7563.2010.01354.x